Opdivo (nivolumab) is an antibody pharmaceutical. Nivolumab was first approved as Opdivo on 2014-12-22. It is used to treat kidney neoplasms, lymphoma, melanoma, non-small-cell lung carcinoma, and squamous cell carcinoma amongst others in the USA. It has been approved in Europe to treat colorectal neoplasms, hodgkin disease, melanoma, mesothelioma, and non-small-cell lung carcinoma amongst others. The pharmaceutical is active against programmed cell death protein 1.
|Indication||colorectal neoplasms, hodgkin disease, kidney neoplasms, lymphoma, melanoma, mesothelioma, non-small-cell lung carcinoma, renal cell carcinoma, squamous cell carcinoma, squamous cell carcinoma of head and neck, transitional cell carcinoma, urinary bladder neoplasms, urologic neoplasms|
|Drug Class||Monoclonal antibodies: fully human, immunomodulating|